Introduction {#s1}
============

Hedgehog (Hh) signaling is critically important during embryonic development and its aberrant regulation is associated with common, lethal birth defects and cancers. Conserved roles as a morphogen and in tissue homeostasis make Hh signaling fundamental to most forms of metazoan life ([@bib7]; [@bib28]; [@bib34]).

Smoothened (Smo) and Patched (Ptch; Ptch1 and Ptch2 in amniotes) are conserved multipass transmembrane proteins required for proper Hh pathway transduction. Smoothened is a putative G-protein-coupled receptor and Ptch has homology to a family of proton-driven antiporters. The regulatory relationship between Ptch and Smo has been the subject of much study, resulting in the following model: (1) Ptch in its unbound state inhibits Smo cell autonomously (2) Hh ligand bound to Ptch releases this inhibition and (3) uninhibited Smo redistributes in the cell and activates transcription of target genes through downstream factors.

While this model has wide acceptance, the Ptch-dependent mechanism responsible for Smo repression has proven elusive. Ptch belongs to the Resistance, Nodulation and Division (RND) family of proton-driven, trimeric efflux pumps that are ubiquitously present in all studied organisms ([@bib40]). RNDs secrete diverse molecular cargos, including lipophilic and amphiphilic molecules such as antibiotics and sterols. They are well studied in Gram-negative bacteria, where they confer multidrug resistance via antibiotic efflux ([@bib50]).

According to prevailing models, Ptch inhibits Smo sub-stoichiometrically rather than through a direct binding relationship, by regulating the localization of a Smo regulatory molecule ([@bib49]). Despite the discovery of exogenous and endogenous molecules capable of regulating Smo, no Smo-regulatory Ptch substrate has been identified ([@bib46]). Nevertheless, several observations indicate that the endogenous cargo of Ptch is a steroidal molecule: (1) the plant-derived steroidal alkaloid cyclopamine binds Smo and inhibits the Hh response ([@bib11]; [@bib29]); (2) heterologous Ptch expression in yeast enhances BODIPY-cholesterol efflux ([@bib4]); (3) the closest prokaryotic homolog of Ptch, HpnH, transports bacterial sterols (hopanoids) from the inner to the outer bacterial membrane ([@bib18]); (4) 7-dehydroxycholesterol reductase (7DHCR), catalyzes the conversion of 7DHC into cholesterol and genetic loss of *7dhcr* is associated with defects in Shh signaling, perhaps via accumulation of a late sterol precursor (or its derivative) that inhibits Smo ([@bib5]; [@bib15]; [@bib25]; [@bib30]; [@bib36]; [@bib45]); (5) Ptch has a sterol-sensing domain (SSD) that is conserved within sterol biogenesis regulatory enzymes, and thus likely binds sterols ([@bib33]), and this domain is necessary for Smo inhibition by Ptch in *Drosophila* ([@bib47]). Within the third transmembrane domain of the SSD (the fourth transmembrane domain of Ptch1) resides a universally conserved Aspartic acid residue that when mutated in bacterial RNDs blocks transport ([@bib55]). Mutation of this residue in Ptch1 yields an allele unable to inhibit Smo both in vivo and in vitro ([@bib1]; [@bib47]; [@bib48]). These observations have led to the hypothesis that Ptch1/2 re-localizes a cholesterol precursor that is inhibitory to Smo ([@bib29]).

As a proton-driven antiporter of the RND family, Ptch1/2 is predicted to secrete its cargo. The observation that murine fibroblasts overexpressing Ptch1 can condition their supernatant with a Smo inhibitor supports this notion ([@bib5]). However, few reports address non-cell-autonomous Smo regulation by Ptch1 antiporter activity. This may be due to other non-cell autonomous mechanisms of Ptch-mediated inhibition unrelated to its antiporter activity, such as its proposed ability to sequester Hedgehog ligands from the environment and thus suppress the Hh response ([@bib13]; [@bib32]; [@bib39]; [@bib47]). Ligand sequestration by Ptch thus complicates efforts to assess non-cell autonomous antiporter-mediated Ptch activity. Besides these possible non-cell autonomous activities, Ptch plays a cell autonomous role in the activation of Smo via the accumulation of phosphatidylinositol 4-phosphate ([@bib35]; [@bib54]) that can activate Smo via its intracellular C-terminal domain.

We attempted to address the non-cell autonomous contribution of Ptch1/2 to Smo regulation with genetically mosaic neural tissue derived from genome-edited mouse embryonic stem cells (mESCs). As a morphogen, Sonic Hedgehog (Shh) patterns the embryonic vertebrate neural tube through a well-studied transcriptional response ([@bib14]; [@bib43]). Shh is expressed ventrally in embryos in the notochord and floor plate, yielding a ventral to dorsal gradient of Hh pathway activity in which ventral cell types have a high level of pathway activation. We can effectively model these signaling events in vitro by differentiating genetically distinct stem cells into neuralized embryoid bodies (nEBs) ([@bib38]; [@bib52]). nEBs have previously been shown to be highly responsive to Shh, the Smo agonist SAG, and cyclopamine, indicating that Smo activity is subject to regulation in this system ([@bib20]). We have also found that Smo becomes maximally activated in nEBs lacking Ptch1 and Ptch2 ([@bib1]).

In our experimental approach, cells in one compartment of genetically mosaic nEBs are either proficient or genetically null for *Ptch1/2*. We measured Hh pathway activity, and thus assess Ptch1/2-mediated non-cell autonomous Smo inhibition in a separate mosaic compartment designed to have active Smo. If the null hypothesis of Ptch1/2 as strict cell-autonomous Smo inhibitors is true, we predict that in mosaic tissues in which cell differ in regard to their Ptch1/2 status the resulting level of Hh response is the average of both constituent cells cultured alone. A rejected null hypothesis supports the notion that Ptch1/2 can inhibit Smo activity non-cell autonomously.

Using genome editing with Tal endonucleases (TALENs) and CRISPR/Cas9, we generated mESC lines genetically null for *Ptch1, Ptch2, Smo, Shh* and *7dhcr* in many combinations. We show that each cell line differentiates as monotypic nEBs to neural progenitor fates predicted according to the established Hh signaling model. We then demonstrate that within genetically mosaic nEBs, cells with Ptch1/2 activity inhibit the Hh response non-cell autonomously in neighboring cells deficient for Ptch1/2 that contain activated Smo. Ptch1/2 also inhibits the response of neighboring wild-type cells to Shh and the Smo agonist SAG. Loss of 7DHCR activity results in an increased ability of Ptch1/2 proficient cells to inhibit the Hh response non-cell autonomously. We attribute these observations to a fundamental function of Ptch1/2 in secreting a steroidal Smo inhibitor via its proton antiporter activity.

Results {#s2}
=======

Ptch1/2 activity inhibits Smo both cell autonomously and non-cell autonomously {#s2-1}
------------------------------------------------------------------------------

In order to assess if Ptch1/2 activity inhibits Smo in neighboring cells, we established a panel of genome-edited mESC lines harboring null mutations in the Hh pathway genes *Ptch1, Ptch2, Smo* and *Shh*. We then co-cultured these cell lines in genetically mosaic nEBs. We used pre-existing mutant cell lines and TAL effector endonucleases (TALENs) to generate our initial mESC panel ([@bib10]). This approach presents an in vitro model in which we can measure the non-cell autonomous effects of Ptch1/2 by varying the Ptch1/2 status of cells and measuring the effect on the Hh response in a specific subset of neighboring cells.

Before using these cell lines in genetically mosaic experiments, we first confirmed that nEBs derived from each cell line in our panel differentiated as expected, given their *Ptch1, Ptch2, Shh* and *Smo* genotype. We predicted that upon neural differentiation each cell line would acquire a neural progenitor identity reflecting the status of its core Hh pathway regulatory genes. Immunostaining for four markers of distinct neural progenitor populations along the vertebrate dorsoventral axis was quantified in order to assess identity. Nkx2.2, Olig2 and Isl1/2 served as markers of ventral cell populations with high Hh activity, while Pax7 designated dorsal tissue where the pathway is silent.

The prevailing model for Hh signaling in the neural tube guided our predictions for each cell line. For example, *Ptch1*^+/LacZ^;*Shh*^-/-^ mESCs yielded nEBs with little Hh pathway activity and thus high dorsal identity, as indicated by a gain of dorsal Pax7^+^ cells to levels greater than wild type ([Figure 1A,B,J,K](#fig1){ref-type="fig"}). Because *Shh* encodes an activating factor, and Pax7^+^ cells indicate pathway quiescence, this cell line differentiated in the manner predicted. *Ptch1*^LacZ/LacZ^ nEBs by contrast were highly ventral ([Figure 1D,M](#fig1){ref-type="fig"}), corroborating previous reports using this cell line, and supporting the canonical view that Ptch1 is a negative pathway regulator (*Ptch1*^LacZ^ is an established null allele \[[@bib24]; [@bib44]\]). Shh signaling through Ptch2 in cells null for *Ptch1* has also been observed and thus unsurprisingly *Ptch1*^LacZ/LacZ^;*Shh*^-/-^ nEBs had reduced numbers of Nkx2.2^+^/Olig2^+^ cells ([Figure 1E,N](#fig1){ref-type="fig"}), compared to *Ptch1*^LacZ/LacZ^ nEBs, indicating ligand dependency of the response. As previously reported, *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ nEBs differentiated into identities associated with high Hh pathway activity, indicated by robust Nkx2.2, Isl1/2 and Olig2 expression ([Figure 1G,P](#fig1){ref-type="fig"}) ([@bib1]). *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ nEBs had unaffected ventral identity ([Figure 1H,Q](#fig1){ref-type="fig"}), consistent with a model for Shh-independent Hh pathway activation in the dual absence of Ptch1/2. Smo was invariably required for the activation of the Hh pathway, as established models predict. *Ptch1*^LacZ/LacZ^;*Smo*^-/-^ and *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Smo*^-/-^ nEBs were entirely lacking Nkx2.2, Isl1/2 and Olig2 expression and instead expressed Pax7, as did *Smo*^-/-^ nEBs ([Figure 1C,F,I,L,O,R](#fig1){ref-type="fig"}). All *Smo*^-/-^ nEBs thus conformed to the standard signaling model by acquiring highly dorsal fates as cells refractory to Shh pathway activation. Each clone had abundant Pax6^+^ nuclei and Tuj1 expression, suggesting robust neuralization ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).10.7554/eLife.17634.002Figure 1.Ptch1/2 disruption enhances Smo-dependent activation of the Hh response.(**A**--**I'**) Genome-edited mESCs with various genotypes were differentiated into nEBs and stained for ventral markers Nkx2.2 (Cyan), Olig2 (Magenta) and Isl1/2 (Red), indicating Hh pathway activation, and the dorsal marker Pax7 (Green) indicating Hh pathway inactivity. (**J**--**R**) Nkx2.2, Isl1/2, Olig2 or Pax7 staining quantification (box and whiskers). WTnEBs have a quiescent Hh response (**A**,**A'**,**J**). Loss of *Shh (Ptch1*^+/L^ (**B**,**B'**,**K**) or *Smo (Smo*^-/-^) (**C**,**C'**,**L**) in cells with intact Ptch1/2 function (Ptch1*^LacZ^*is null) increases Pax7. nEBs without Ptch1 (*Ptch1*^LacZ/LacZ^, **D**,**D'**,**M**) have an activated Hh response. Loss of Shh (*Ptch1*^LacZ/LacZ^;*Shh*^-/-^, **E**,**E'**,**N**) decreases the response. *Ptch1*^LacZ/LacZ^;*Smo*^-/-^ nEBs acquire Pax7 (**F**,**F'**,**O**) and are devoid of all three ventral markers. nEBs lacking all Ptch1/2 activity (*Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^) have an activated Hh response pathway (**G**,**G'**,**P**). *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ nEBs retain similar ventral identity (**H**,**H'**,**Q**). *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Smo*^-/-^ nEBs lose ventral identity and express Pax7 (**I**,**I'**,**R**). Scale bar is 100 µm. (**S**) Nkx2.2 and Isl1/2 expression in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ nEBs is quantified (box and whisker) in the presence of 0--300 nM cyclopamine. (**T**) *Ptch1*^+/LacZ^;*Shh*^-/-^ and *Ptch1*^LacZ/LacZ^;*Shh*^-/-^, but not *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ retain their ability to respond to exogenously supplied ShhN by inducing Nkx2.2 expression. (**U**) Fibroblast-like cells derived from *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ mESCs were transfected with a *Gli:luciferase* construct alone or together with *Ptch1*. Independently, *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ cells were mock transfected or transfected with *ShhN*. Gli:Luciferase is quantified in co-cultures. *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ cells expressing Ptch1 can respond to ShhN supplied in co-cultured cells. p-value is indicated, n = 6. Variance is s.e.m. in **A**--**U**.**DOI:** [http://dx.doi.org/10.7554/eLife.17634.002](10.7554/eLife.17634.002)10.7554/eLife.17634.003Figure 1---figure supplement 1.Neural differentiation proceeds normally in all modified cell lines.Cell lines used were stained for Pax6, HB9, Isl1/2 and Tuj1 expression after in vitro neuralization. Although not all nEBs were equally sized, invariably they express Pax6 and Tuj1, indicating the acquisition of neural progenitor fates, regardless of their genotype (indicated). Scale bar is 100 µm. One biological replicate performed.**DOI:** [http://dx.doi.org/10.7554/eLife.17634.003](10.7554/eLife.17634.003)

Because of their high level of Hh pathway activity, we used *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ mESCs as sensitized cells in which non-cell autonomous Smo-inhibitory effects mediated by Ptch1/2 in adjacent cells could be measured. We reasoned that genetic ablation of both Ptch1 and Ptch2 would be necessary to assess non-cell autonomous Smo regulation in these cells because Ptch2 compensates for Ptch1 loss in cell autonomous Smo regulation ([@bib1]; [@bib57]). We previously reported that the Hh pathway in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ nEBs could not be further activated by the Smo agonist SAG ([@bib12]), suggesting maximal Smo activation in the absence of Ptch1/2. To assess ligand-independent cell non-autonomous signaling, *Shh*^-/-^ cells were necessary because Shh is expressed in *Ptch1*^-/-^; *Ptch2*^-/-^ nEBs and the *Ptch1*^-/-^ mouse neural tube ([@bib1]; [@bib24]).

We validated that *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cells differentiate into ventral neural fates in a Smo-dependent, Shh-independent manner. First, we treated nEBs with the Smo inhibitor cyclopamine ([@bib16]; [@bib22]; [@bib30]) and found that cyclopamine inhibited Isl1/2 and Nkx2.2 expression with an IC~50~ around 25 nM ([Figure 1S](#fig1){ref-type="fig"}). We found that ShhN (soluble N-terminal Shh) was able to induce the Hh response both in *Ptch1*^+/LacZ^;*Shh*^-/-^ and *Ptch1*^LacZ/LacZ^;*Shh*^-/-^ nEBs but not in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ nEBs, ([Figure 1T](#fig1){ref-type="fig"}), corroborating our report that *Ptch1*^-/-^ cells respond to Shh via Ptch2 ([@bib1]). To test if the response to Shh can be restored in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ cells by Ptch1 expression, we derived a fibroblast-like cell line ([@bib2]; [@bib26]). Despite Ptch1/2 absence, these cells have low Hh pathway activation, resembling 24--48 hr nEBs, allowing us to assess Hh pathway induction (Figure 3C). *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ fibroblasts co-transfected with *Gli:Luciferase*, a Hh pathway reporter ([@bib48]) and *Ptch1*, then co-cultured with *ShhN*-transfected cells, activate the Hh response ([Figure 1U](#fig1){ref-type="fig"}). ShhN alone was unable to activate the Hh pathway in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ cells, consistent with results obtained with nEBs ([Figure 1T](#fig1){ref-type="fig"}). Thus, the ability to respond to exogenous ShhN is lost in the absence of Ptch1/2, but can be restored with *Ptch1* transfection.

We first assayed non-cell autonomous Ptch1/2 inhibition of Smo-mediated neural differentiation by determining whether *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cells have diminished ventral progenitors when co-cultured in mosaic nEBs with *Ptch1*^+/LacZ^;*Shh*^-/-^ cells, thus rejecting the null hypothesis of Ptch1/2 acting strictly cell autonomously ([Figure 2A](#fig2){ref-type="fig"}). Relative to *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ nEBs, *Ptch1*^+/LacZ^;*Shh^-/-^* nEBs are devoid of Nkx2.2^+^ cells and highly diminished for Olig2^+^ cells ([Figure 2B](#fig2){ref-type="fig"}), presumably because Smo is under Ptch1/2-mediated repression. Interestingly, mosaic nEBs comprised 1:1 of the two cell lines resembled *Ptch1*^+/LacZ^;*Shh*^-/-^ nEBs as judged by their near complete absence of Nkx2.2^+^ cells, and had fewer Olig2^+^ cells than expected for a 1:1 mosaic. Because Shh is genetically absent from these nEBs and *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ mESCs are ligand insensitive, we interpreted this result as consistent with extracellular flux of Ptch1/2 substrates from *Ptch1*^+/LacZ^;*Shh*^-/-^ mESCs in which Ptch1/2 are intact, and inconsistent with Shh sequestration from this compartment of cells.10.7554/eLife.17634.004Figure 2.The Hh response in cells lacking Ptch1/2 can be inhibited non-cell autonomously by Ptch1/2 competent cells.(**A**) Diagram showing the experimental approach. Rejection of the null hypothesis provides evidence for non-cell autonomous activity of Ptch1/2. (**B**) Mosaic nEBs consisting 1:1 of *Ptch1*^+/LacZ^;*Shh*^-/-^ and *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells have fewer Nkx2.2^+^ and Olig2^+^ cells than predicted based on unmixed *Ptch1*^+/LacZ^;*Shh*^-/-^ and *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ nEBs (null hypothesis values, dotted lines). (**C**) Representative images of **B**, Scale bar is 50 µm. Two biological replicates were performed in **B**.**DOI:** [http://dx.doi.org/10.7554/eLife.17634.004](10.7554/eLife.17634.004)10.7554/eLife.17634.005Figure 2---figure supplement 1.Acquisition of a more dorsal identity in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cells results in an increase in Olig2^+^ cells at the expense of Nkx2.2^+^ cells.nEBs cultured with equal contributions of *Ptch1*^LacZ/LacZ;^*Ptch2*^-/-^;*Shh*^-/-^ cells and either *Smo*^-/-^ or *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Smo*^-/-^ cells were quantified for the number of Nkx2.2^+^ and Olig2^+^ cells. Cells lacking *Smo* never have an upregulated Shh response, confining Nkx2.2^+^ and Olig2^+^ staining to *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells. *Smo*^-/-^ cells with intact Ptch1/2 cause a loss in the predicted number of Nkx2.2^+^ cells, and an increase in Olig2^+^ cells, indicating a less ventral identity in the *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells as a consequence of Ptch1/2 activity in the surrounding cells. Diagram depicts how a subtle dorsalization in the identity of *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells can increase Olig2 expression while decreasing Nkx2.2 expression.**DOI:** [http://dx.doi.org/10.7554/eLife.17634.005](10.7554/eLife.17634.005)

We next assayed the differentiation of *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cells when co-cultured 1:1 in mosaic nEBs with either *Smo^-/-^*or *Ptch1*^-/-^*;Ptch2*^-/-^*;Smo*^-/-^ mESCs. We reasoned that ablating Smo would decouple cell autonomous cell fate decisions from Ptch1/2 status. Because we find that *Smo*^-/-^ nEBs retain dorsal identity (Pax7^+^ cells) regardless of their Ptch1/2 status ([Figure 1C,L,F,O,I,R](#fig1){ref-type="fig"}), we expected markers of ventral identity in mosaic nEBs to be lineage restricted to the *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cell compartment, and that differences in Nkx2.2^+^/Olig2^+^ progenitors in that compartment would reflect Smo repression from Ptch1/2 in neighboring *Smo*^-/-^ cells. We thus expected *Ptch1*^-/-^*;Ptch2*^-/-^*;Smo*^-/-^ cells to have no effect. nEB mosaics of *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ and *Ptch1*^-/-^*;Ptch2*^-/-^*;Smo*^-/-^ co-cultured at 1:1 ratios met expectations by containing half as many Nkx2.2^+^/Olig2^+^ progenitors as *Ptch1*^-/-^*;Ptch2*^-/-^*;Shh*^-/-^ nEBs. This indicates a lack of Ptch1/2-mediated Smo repression in the tissue ([Figure 2B](#fig2){ref-type="fig"}). In contrast, co-culture of *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cells with *Smo*^-/-^ cells significantly decreased Nkx2.2^+^ cells and increased Olig2^+^ cells, rejecting the null hypothesis. We interpret this as a dorsal shift in the identity of the *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cell compartment, as Nkx2.2 is a marker of a more ventral neural progenitor domain than Olig2 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We attribute this relatively mild effect to low levels of Ptch1/2 activity in *Smo*^-/-^ cells.

Gene editing in a Disp1^-/-^ background reveals non-cell autonomous regulation of Smo-mediated Ptch1:LacZ expression in mosaic nEBs {#s2-2}
-----------------------------------------------------------------------------------------------------------------------------------

As an independent and more rapid assay for non-cell autonomous effects of Ptch1/2 on Smo we assessed Ptch1:LacZ induction ([@bib24]) in nEBs using *Ptch1*^+/LacZ^ and *Ptch1*^LacZ/LacZ^ mESCs, and edited cell lines derived from them. Before employing this assay in mosaic nEBs, we investigated whether Ptch1:LacZ induction mirrored ventral neural progenitor differentiation ([Figure 1](#fig1){ref-type="fig"}) in our cell line panel. At 72 hr, Ptch1:LacZ levels were low in *Ptch1*^+/LacZ^ and *Ptch1^+/^*^LacZ^;*Shh*^-/-^ nEBs but robust in *Ptch1*^LacZ/LacZ^ and *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ nEBs ([Figure 3A](#fig3){ref-type="fig"}). Ptch1:LacZ levels were reduced in *Ptch1*^LacZ/LacZ^;*Shh*^-/-^ nEBs but remained elevated in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ nEBs. *Ptch1*^LacZ/LacZ^*;Smo*^-/-^ *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Smo*^-/-^ nEBs had reduced Ptch:LacZ despite Ptch1/2 loss. *Smo*^-/-^ mESCs were derived previously and constitutively express Rosa26:LacZ ([@bib56]). These measurements corroborate our findings in monotypic nEBs with neural progenitor markers and support a role for Smo-dependent, Shh ligand-mediated signaling in nEBs lacking Ptch1 (but not Ptch2), and the loss of Shh dependence in the complete absence of Ptch1/2 ([Figure 3A](#fig3){ref-type="fig"}). These data suggest that Ptch1:LacZ is a reliable output for Hh pathway activity across cell lines. We performed a time-course experiment to more precisely establish the point of maximal pathway activation. We found that Ptch1:LacZ was strongly induced in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ nEBs after 72 hr differentiation ([Figure 3C](#fig3){ref-type="fig"}), and this high level of expression persisted for several days. Ptch1:LacZ expression is suppressed after treatment with cyclopamine, indicating that Ptch1:LacZ upregulation requires Smo ([Figure 3B](#fig3){ref-type="fig"}).10.7554/eLife.17634.006Figure 3.Ptch1/2 inhibit Ptch1:LacZ expression both cell autonomously and non-cell autonomously.(**A**) Ptch1:LacZ is a lineage-restricted measure of *Ptch1* expression, and thus Hh pathway activity. *Ptch1:LacZ* is activated by sequential loss of Ptch1/2, and this activation requires Smo activity. Genetic loss of *Shh* reduces the level of Hh pathway activation in *Ptch1*^LacZ/LacZ^, but not in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ cells (**B**) *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ nEBs were cultured in 0--300 nM cyclopamine and Ptch1:LacZ was measured at 72 hr. Ptch1:LacZ levels in 30 nM cyclopamine were approximately half those of untreated nEBs. (**C**) Ptch1:LacZ levels were measured up to 5 days after nEB formation. (**D**--**I**) Additional loss of *Disp1* does not alter the consequences of the loss of Ptch1/2 activity on neural progenitor identity. (**J**) Ptch1:LacZ expression in mosaic nEBs consisting of 50% *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells and 50% *Disp1*^-/-^;*Shh*^-/-^, *Disp1*^-/-^;*Shh*^-/-^;*Ptch1*^-/-^, or *Disp1*^-/-^;*Shh*^-/-^;*Ptch1*^-/-^;*Ptch2*^-/-^ cells (indicated). Ptch1:LacZ levels in the *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells were assessed after 72 hr in culture. LacZ levels were compared to half (red dotted line, signifying the null hypothesis) the LacZ activity measured in nEBs comprised of 100% *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells. Error bars are s.d., p-values are indicated (t-test, n = 3 measurements) and relate to comparison of each value with the null hypothesis. *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Smo*^-/-^ cells have a low Ptch1:LacZ activity in this assay regardless of the genotype of the surrounding cells. (**K**) *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ mESCs were loaded with green fluorescent cell tracker dye, and the *Disp1*^-/-^;*Shh*^-/-^, *Disp1*^-/-^;*Shh*^-/-^;*Ptch1*^-/-^, and *Disp1*^-/-^;*Shh*^-/-^;*Ptch1*^-/-^;*Ptch2*^-/-^ mESCs with blue fluorescent dye (magenta). Mosaic nEBs as described in **A** were cultured for 48 hr, and imaged. 1:1 contribution reflecting the initial mosaic contributions is maintained throughout the experiment. *p* values are indicated (t-test). **D**--**I** are box-and-whisker plots.**DOI:** [http://dx.doi.org/10.7554/eLife.17634.006](10.7554/eLife.17634.006)

To assess non-cell autonomous Ptch1/2 activity in a mosaic nEB assay using Ptch1:LacZ, we expanded our panel of mutant cell lines to include cells variable for Ptch1/2 status in *Disp1*^-/-^ mESCs ([@bib19]). We observed robust ventral neural progenitor identity only in *Disp1*^-/-^;*Ptch1*^-/-^;*Ptch2*^-/-^;*Shh*^-/-^ nEBs (*Ptch1*^LacZ^ and *Ptch1*^-^ distinguish null *Ptch1* alleles in these two families of cell lines). By contrast *Disp1*^-/-^;*Shh*^-/-^ and *Disp1*^-/-^;*Ptch1*^-/-^;*Shh*^-/-^ had widespread Pax7^+^ progenitors, indicating a low level of Hh pathway activation ([Figure 3D--I](#fig3){ref-type="fig"}).

*Disp1*^-/-^ mESCs are devoid of LacZ and in co-cultures we can, therefore, strictly measure cell-non autonomous Smo regulation in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells. Additionally, using *Disp1*^-/-^ cells in this assay ensures that Dhh and Ihh cannot compensate for *Shh* ablation, because all Hh ligands require Disp1 to mediate paracrine effects ([@bib19]; [@bib37]). Nevertheless, we genetically inactivated Shh in these cell lines as an additional safeguard against possible juxtacrine signaling by Shh ([@bib9]; [@bib19]; [@bib51]).

We measured Ptch1:LacZ expression in mosaic nEBs at 72 hr when Ptch1:LacZ measurement reaches its maximum ([Figure 3C](#fig3){ref-type="fig"}). *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ nEBs mosaic 1:1 with *Disp1*^-/-^*;Shh*^-/-^*;Ptch1*^-/-^*;Ptch2*^-/-^ cells yielded Ptch1:LacZ signal closely reflecting the relative mESC contribution of *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cells. However, when *Disp1*^-/-^*;Shh*^-/-^ or *Disp1*^-/-^;*Shh*^-/-^*;Ptch1*^-/-^ cells were co-cultured with *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cells, Ptch1:LacZ levels in the *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cells significantly declined ([Figure 3J](#fig3){ref-type="fig"}). By contrast, only small differences were found in Ptch1:LacZ signal derived from *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Smo*^-/-^ mESCs co-cultured 1:1 with *Disp1*^-/-^*;Shh*^-/-^, *Disp1*^-/-^;*Shh*^-/-^*;Ptch1*^-/-^ or *Disp1*^-/-^*;Shh*^-/-^*;Ptch1*^-/-^*;Ptch2*^-/-^ cells. This supports the notion that Smo is the target of the inhibitory cargo of Ptch1/2 activity. Labeling the two cell compartments using Cell Tracker dyes, and assessing the resulting mosaic nEBs showed equivalent relative contributions after 48 hr ([Figure 3K](#fig3){ref-type="fig"}), indicating that changes in LacZ levels in mosaic nEBs are not attributable to disparities in cell growth or adhesion during the culture period. These results suggest that endogenous Ptch1/2 suppress the Hh response non-cell autonomously in cells lacking Ptch1/2 activity.

The loss of 7dhcr enhances the ability of cells to inhibit the Hh response pathway non-cell autonomously {#s2-3}
--------------------------------------------------------------------------------------------------------

We assessed 7-dehydroxycholesterol (7DHC), or one of its derivatives ([@bib5]; [@bib45]) as a candidate for the Ptch1/2 cargo mediating non-cell autonomous Smo inhibition. *7dhcr* mutations are associated with Shh signaling defects caused by the accumulation of a late sterol precursor (or its derivative) that inhibits Smo, according to the prevailing hypothesis ([@bib5]; [@bib15]; [@bib25]; [@bib30]). We thus tested whether loss of *7-Dehydroxycholesterol Reductase (7dhcr*) enhances Ptch1/2-mediated inhibition of Smo in adjacent *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^*;Shh*^-/-^ cells.

Using CRISPR/Cas9 gene editing ([@bib17]), we inactivated *7dhcr* in previously edited *Shh*^-/-^ mESCs devoid of LacZ, adding *Shh*^-/-^;*7dhcr*^-/-^ cells to our panel of mutant cell lines. We generated 1:1 mosaic nEBs consisting of *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^*;Shh*^-/-^ cells and either *Shh*^-/-^ or *Shh*^-/-^;*7dhcr*^-/-^ cells ([Figure 4A](#fig4){ref-type="fig"}) and measured Hh pathway activation exclusively in the *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^*;Shh*^-/-^ cell population via Ptch1:LacZ. Differences in Ptch:LacZ levels were thus attributable to differing degrees of cell non-autonomous regulation by the other cell compartment. Significantly less Ptch1:LacZ signal was obtained from nEBs containing *Shh*^-/-^;*7dhcr*^-/-^ cells as compared with nEBs containing parental *Shh*^-/-^ cells ([Figure 4B](#fig4){ref-type="fig"}). Cell tracker dyes used to label each cell compartment indicated that all cell lines contributed to mosaic nEBs equally ([Figure 4A](#fig4){ref-type="fig"}). Because nEBs are cultured in a cholesterol-free environment, they likely upregulate cholesterol synthesis ([@bib8]). Accumulation of 7DHC, or a 7DHC derivative ([@bib5]; [@bib45]) in *Shh*^-/-^;*7dhcr*^-/-^ cells may thus provide a larger pool of the Ptch1/2 cargo, increasing secretion of the Smo-inhibitory sterol, possibly 7DHC.10.7554/eLife.17634.007Figure 4.Loss of *7dhcr* enhances non-cell autonomous suppression of the Hh response.(**A**) nEBs consisting of 50% *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells (green) and 50% *Shh*^-/-^ cells or 50% *Shh*^-/-^; *7dhcr* ^-/-^ cells (magenta) were labeled with cell tracking vital dyes. (**B**) LacZ quantification in nEBs described in (**A**). 7*dhcr* ablation enhances non-cell autonomous inhibition of the Hh response in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells. (**C**) The Hh response in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells is inhibited by 7-Dehydrocholesterol (7DHC) as compared to cholesterol. The ability of 7DHC to inhibit the Hh response in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells is exacerbated by the inclusion of *Shh*^-/-^ cells, and to a lesser extent by *Shh*^-/-^;*7dhcr*^-/-^ cells. n \> 8, \*p\<0.05, \*\*\*p\<0.001, n.s., not significant (t-test).**DOI:** [http://dx.doi.org/10.7554/eLife.17634.007](10.7554/eLife.17634.007)

To further test the role of 7DHC in Smo inhibition, we cultured *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^*;Shh*^-/-^ nEBs in its presence. Corroborating earlier findings ([@bib5]), we observed a decreased Hh response in nEBs treated with 7DHC compared to control treatment with cholesterol, regardless of whether the nEB was mosaic or comprised exclusively of *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^*;Shh*^-/-^ cells ([Figure 4C](#fig4){ref-type="fig"}). We additionally saw differences between the mosaic nEBs. A larger inhibition of the Hh response by exogenous 7DHC was observed in *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^*;Shh*^-/-^ cells co-cultured 1:1 in nEBs with *Shh*^-/-^ as opposed to *Shh*^-/-^;*7dhcr*^-/-^ cells ([Figure 4C](#fig4){ref-type="fig"}). We speculate that cells containing Ptch1/2 may be able to process or transport exogenous 7DHC into a more potent non-cell autonomous inhibitor of the Hh response in neighboring *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^*;Shh*^-/-^ cells, and that this effect is further enhanced in cells genetically intact for *7dhcr* and presumably producing endogenous 7DHC, in addition to the exogenous source. These findings are consistent with Ptch1/2 antiporter activity mediating secretion of 7DHC, or an oxysterol derivative like 3β,5α-dihydroxycholest-7-en-6-one ([@bib45]), as a mechanism to inhibit Smo in neighboring cells.

Motor neuron differentiation in wild-type HB9:GFP cells is attenuated by Ptch1/2 in nearby cells via a SAG-competitive mechanism {#s2-4}
--------------------------------------------------------------------------------------------------------------------------------

Motor neurons arise from a population of neural progenitors in the ventral neural tube, and Hh pathway activation is required for motor neuron differentiation in vivo as well as in nEBs. We used the induction of GFP in HB9:GFP ([@bib52]) mESCs as an independent lineage-restricted measure of the Hh response in genetically mosaic nEBs. HB9:GFP^+^ cells had motor neuron morphology and co-labeled with Isl1/2 immunostain, and thus serve as a measure for motor neuron induction ([Figure 5B](#fig5){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Mosaic nEBs consisting of *Ptch1*^+/LacZ^*;Shh*^-/-^*, Ptch1*^LacZ/-^*;Shh*^-/-^ or *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ mESCs mixed 10:1 with HB9:GFP mESCs were generated. We observed a small but significant increase in HB9:GFP*^+^*motor neurons when these cells were co-cultured with *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^;*Shh*^-/-^ cells as compared to *Ptch1*^+/LacZ^*;Shh*^-/-^ or *Ptch1*^LacZ/-^*;Shh*^-/-^ cells ([Figure 5A,C](#fig5){ref-type="fig"}).10.7554/eLife.17634.008Figure 5.The Hh response to the Smo agonist SAG in HB9:GFP cells is enhanced by the absence of Ptch1/2 in neighboring cells.(**A**) Images of mosaic nEBs consisting of 10% HB9:GFP cells and 90% *Ptch1*^+/LacZ^;*Shh*^-/-^, *Ptch1*^LacZ/-^;*Shh*^-/-^ or *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ cells (indicated). Mosaic nEBs were cultured in 0 nM (blue), 10 nM (red) or 100 nM (green) SAG. GFP expression in HB9:GFP cells indicates motor neuron differentiation, a measure of Hh pathway upregulation. (**B**) Isl1/2 (magenta) and HB9:GFP (green) is largely confined to the same cells, indicating that HB9:GFP serves as a motor neuron marker. (**C**) HB9:GFP^+^ cells were quantified. n \> 20, \*\*p\<0.01, \*\*\*p\<0.001, n.s., not significant (t-test). Scale bar is 100 µm for **A**, 200 µm for **B**.**DOI:** [http://dx.doi.org/10.7554/eLife.17634.008](10.7554/eLife.17634.008)

While we hypothesize that Ptch1/2-expressing cells produce a Smo inhibitor, it remains a formal possibility that cells lacking Ptch1/2 have an activating effect on nearby cells. This activating activity could be indirect in that Shh potentially produced by HB9:GFP cells would no longer be sequestered by Ptch1/2 in adjacent cells ([Figure 1T](#fig1){ref-type="fig"}), making Shh available to the HB9:GFP cells themselves. To discriminate between these possibilities, we treated mosaic nEBs with SAG, a small molecule Smo agonist thought to antagonize the Smo-inhibitory Ptch1/2 substrate ([@bib11]; [@bib46]). We expected decreased availability of the inhibitor, due to Ptch1/2 absence in neighboring cells, to enhance SAG effects. If cells lacking Ptch1/2 release an activator of the Hh response, its effects in combination with SAG are expected to be additive.

As predicted, 10 nM and 100 nM SAG induces motor neuron differentiation in HB9:GFP cells under all mosaic conditions ([Figure 5A](#fig5){ref-type="fig"}). However, a strong synergistic effect was observed between Ptch1/2 loss in surrounding cells and SAG-induced motor neuron differentiation in HB9:GFP cells ([Figure 5A,B](#fig5){ref-type="fig"}). We found that compared to *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ cells, *Ptch1*^+/LacZ^;*Shh*^-/-^ cells suppressed motor neuron induction at both SAG concentrations, while *Ptch1*^LacZ/-^*;Shh*^-/-^ cells also suppressed motor neuron induction to an intermediate degree (presumably via Ptch2 activity). This observation is consistent with Ptch1/2 cargo acting as a SAG antagonist and is not easily reconciled with impaired Hh ligand sequestration due to the lack of Ptch1/2 in the environment, as this scenario should have little effect on SAG-mediated Smo activation.

Three-part mosaic nEBs reveal a non-cell autonomous role for Ptch1/2 in regulating the response to Shh ligand {#s2-5}
-------------------------------------------------------------------------------------------------------------

Shh activates Smo activity indirectly, unlike SAG, after first binding Ptch1/2, according to the canonical Hh signaling model ([@bib12]). To determine whether our previous findings apply to signaling by mature Shh ligand, we investigated whether Ptch1/2 within mosaic nEBs inhibit Smo activation in HB9:GFP cells in response to Shh expressed by a third cell population. To accomplish this, we generated three-part mosaic nEBs including 1% wild type cells harboring the EF1α:Shh transgene. These cells functioned as sparse, localized sources of Shh in mosaic nEBs. Effects of Shh produced by these cells were measured in HB9:GFP cells (5% of cells) in mosaic nEBs in which the *Ptch1/2* genotype in the third and predominant compartment (94% of cells) was varied.

Three-part mosaic nEBs consisting of 94% *Ptch1*^LacZ/LacZ^;*Shh*^-/-^ or *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^*;Shh*^-/-^ cells facilitated robust Shh-mediated HB9:GFP^+^ motor neuron induction. In contrast, we observed negligible GFP expression in mosaic nEBs principally comprised of *Ptch1*^+/LacZ^;*Shh*^-/-^ cells ([Figure 6A,D](#fig6){ref-type="fig"}). HB9:GFP^+^ motor neurons were not observed when Shh overexpressing cells were omitted. Thus, the response to Shh is strongly enhanced by Ptch1/2 absence in nearby cells.10.7554/eLife.17634.009Figure 6.Loss of Ptch1 and Ptch2 in neighboring cells enhances the response to Shh in HB9:GFP cells.(**A**--**C**) Images of two-part and three-part mosaic nEBs showing GFP expression in HB9:GFP cells. All nEBs included 5% HB9:GFP cells, and 1% Shh-expressing cells where indicated. (**A**) The remaining 94%/95% of cells were *Ptch1*^+/LacZ^;*Shh*^-/-^, *Ptch1*^LacZ/LacZ^;*Shh*^-/-^ or *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ (indicated). (**B**) The remaining 94%/95% of cells were *Disp1*^-/-^;*Shh*^-/-^, *Disp1*^-/-^;*Shh*^-/-^;*Ptch1*^-/-^, or *Disp1*^-/-^;*Shh*^-/-^*;Ptch1*^-/-^*Ptch2*^-/-^ (indicated). (**C**) Remaining 94%/95% of cells were *Ptch1*^-/-^;*Smo*^-/-^ or *Ptch1*^-/-^;*Ptch2*^-/-^;*Smo*^-/-^ (indicated). Under all conditions, Ptch1/2 absence greatly enhanced Shh-dependent motor neuron differentiation in HB9:GFP cells. (**D**) HB9:GFP^+^ cells in (**A**), (**B**) and (**C**) were quantified per mosaic nEB. (**E**) Images of three-part and four-part mosaic nEBs showing HB9:GFP^+^ cells. All nEBs included 5% HB9:GFP cells and 1% Shh-expressing cells. Remaining cells were *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Shh*^-/-^ (gray) and *Ptch1*^+/LacZ^;*Shh*^-/-^ (blue) in indicated ratios. *Ptch1*^+/LacZ^;*Shh*^-/-^ cells suppress Shh-mediated motor induction. (**F**) HB9:GFP^+^ cells in (**E**) were quantified. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, n.s., not significant (t-test). Scale bar is 100 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17634.009](10.7554/eLife.17634.009)10.7554/eLife.17634.010Figure 6---figure supplement 1.Shh distribution away from the sites of synthesis is not affected by the absence of Ptch1/2 in the tissue.Shh-expressing cells (overexposed after live 5E1 stain) were incorporated into *Shh*^-/-^ tissues lacking combinations of *Ptch*1, *Ptch*2, *Disp*1 and *Smo.* Genotypes are indicated. A *Ptch1*^+/LacZ^;*Shh*^-/-^ EB without embedded Shh-expressing cells is shown in the top left panel. Scale bar is 50 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17634.010](10.7554/eLife.17634.010)

Our experiments with SAG ([Figure 5](#fig5){ref-type="fig"}) make it unlikely that lack of Hh ligand sequestration causes non-cell autonomous enhancement of the Hh response in nEBs lacking Ptch1/2. Nevertheless, we directly tested Shh abundance in mosaic nEBs. Live staining with the anti-Shh monoclonal antibody 5E1 is expected to exclusively bind Shh present in the extracellular space. Moreover, the 5E1 epitope on Shh overlaps with the binding site of Ptch1, preventing visualization of Ptch1/2 sequestered Shh ([@bib21]; [@bib41]). We found no difference in extracellular Shh staining in various mosaic nEBs ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), further supporting the idea that non-cell autonomous inhibition by Ptch1/2 of the Hh response does not involve Shh sequestration.

To address if Ihh or Dhh explained enhanced motor neuron induction in mosaic nEBs, we varied Ptch1/2 status in *Disp1*^-/-^;*Shh*^-/-^ cells, in which Ihh and Dhh are not expected to signal. Shh robustly induced HB9:GFP^+^ motor neurons in nEBs consisting of 94% *Disp1*^-/-^;*Ptch1*^-/-^;*Ptch2*^-/-^;*Shh*^-/-^ cells, while motor neuron induction was negligible in nEBs primarily consisting of 94% *Disp1*^-/-^;*Ptch1*^-/-^;*Shh*^-/-^ and *Disp1*^-/-^;*Shh*^-/-^ cells ([Figure 6B,D](#fig6){ref-type="fig"}). The degree of non-cell autonomous repression of HB9:GFP induction in response to Shh reflects the extent of dorsal identity, and presumably Ptch1/2 activity, in this family of cell lines ([Figure 3D--I](#fig3){ref-type="fig"}).

The activated Hh pathway in Ptch1/2-deficient cells could cause motor neuron induction via unknown downstream factors. To address this, we generated three-part mosaic nEBs using *Ptch1*^-/-^;*Smo*^-/-^ or *Pt*c*h1*^-/-^;*Ptch2*^-/-^;*Smo*^-/-^ mESCs. HB9:GFP^+^ motor neurons were induced efficiently only in predominantly *Pt*c*h1*^-/-^;*Ptch2*^-/-^;*Smo*^-/-^ nEBs ([Figure 6C,D](#fig6){ref-type="fig"}). This observation again supports overlapping non-cell autonomous roles for Ptch1/2.

The inhibitory effects of Ptch1/2 containing cells are dominant over those of cells lacking Ptch1/2 function in four-part mosaic nEBs {#s2-6}
-------------------------------------------------------------------------------------------------------------------------------------

To further exclude the possibility that cells lacking Ptch1/2 produce a Hh pathway inducer, we tested if the non-cell autonomous properties of cells lacking Ptch1/2 are dominant over cells with Ptch1/2 function (suggesting secretion of an inducer) or if the activities associated with Ptch1/2 containing cells are dominant over those lacking Ptch1/2 function (supporting secretion of an inhibitor). We made nEBs that were largely composed of various ratios of *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^*;Shh*^-/-^ and *Ptch1*^+/LacZ^;*Shh*^-/-^ cells, and assessed their effect on the induction of HB9:GFP^+^ cells by Shh-expressing cells. In nEBs largely comprised of *Ptch1*^LacZ/LacZ^*;Ptch2*^-/-^*;Shh*^-/-^ cells, even a minor fraction of *Ptch1*^+/LacZ^;*Shh*^-/-^ cells suppressed motor neuron induction ([Figure 6E,F](#fig6){ref-type="fig"}). This indicates that the properties of Ptch1/2 containing cells are dominant over those of cells lacking Ptch1/2 function, further supporting the notion that Ptch1/2 function mediates the secretion of a Smo inhibitor that de-sensitizes cells to the effects of Shh.

Discussion {#s3}
==========

Mosaic nEBs comprised of mESCs with novel, complex genotypes allow us to study interactions between cell populations with resolution not easily achieved in vivo. Within this system, lineage-restricted reporter cells unambiguously indicate non-cell autonomous Smo inhibition by nearby cells expressing Ptch1/2 at endogenous levels. A logical interpretation of these results is that Ptch1/2 mediate the secretion of a Smo inhibitor that affects the Hh response both cell autonomously, and in nearby cells.

Observations similar to ours but using overexpressed Ptch1 have been reported in fibroblasts and our experiments support this finding ([@bib5]). Detecting these activities of Ptch1/2 expressed at endogenous levels in nEBs resolves the argument that overexpressed Ptch1/2 constructs could have non-physiological effects. Because Shh signaling in nEBs patterns multiple cell fates and mimics neural tube induction, these results are likely relevant to in vivo signaling.

Although all independently derived Ptch1/2 cells were equally unable to inhibit the Hh response non-cell autonomously, we found that independent *Ptch1*^-/-^ lines varied in regard to this activity. Notably, cells with a dorsal identity (*Disp1*^-/-^*;Ptch1*^-/-^*;Shh*^-/-^) are better non-cell autonomous repressors of the Hh response than cells with a more ventral identity (*Ptch1*^LacZ/LacZ^*;Shh*^-/-^). We speculate that this is due to varying levels of Ptch2 activity. It also appears that the loss of Smo decreases the ability of Ptch1/2 to inhibit the Hh response non-cell autonomously. This observation is easily explained by a decrease in Ptch1/2 levels as Ptch1/2 expression is under the control of Smo. Thus, even in the complete absence of Hh pathway activation, Ptch1/2 can still inhibit Smo. This is consistent with the observation that in tissues without detectable levels of Ptch1/2, Smo remains inactive.

Our findings are consistent with Ptch1/2 functioning as proton-driven efflux pumps in the RND family ([@bib40]). RND antiporters utilize a pH gradient to drive transport and Ptch1/2 thus likely function in acidified compartments. We previously demonstrated that Ptch1 localizes to late endosomes while mediating Shh uptake, and that Shh signaling requires endosomal acidification ([@bib31]). Conserved acidic residues required for proton flux in prokaryotic RNDs are also required for Ptch1 to repress Smo ([@bib1]; [@bib47]). One possibility is that Ptch1/2 enrich the endosomal lumen or intraluminal vesicular in multivesicular endosomes (MVEs) with a Smo inhibitor. Exosomal release would allow this inhibitor to enter the extracellular environment and regulate Smo both cell autonomously as well as non-cell autonomously.

Our observation that cells enriched in sterol precursors are better cell non-cell autonomous inhibitors of the Hh response complements earlier observations implicating sterols as the Smo inhibitors transported by Ptch1/2. The observation that 7DHCR loss coincides with reduced Hh signaling is refined by our results showing that Ptch1/2 become more effective non-cell autonomous inhibitors of Smo in nearby cells when expressed in cells enriched for 7DHC or its derivatives.

Why the Smo-inhibitory Ptch1/2 cargo, despite its likely abundance in cells, fails to inhibit Smo without being acted on (cell autonomously or non-cell autonomously) by Ptch1/2 remains unresolved. However, our results show that 7DHC becomes a more potent inhibitor when acted upon by Ptch1/2 activity, and when combined with the evidence that Ptch1/2 function as proton-driven antiporters, it becomes plausible that the Ptch1/2 cargo becomes inhibitory after translocation or secretion. This view is consistent with the known role of the prokaryotic RND HpnN ([@bib18]) that transports bacterial sterols between inner and outer membranes. It would also be consistent with the function of NPC1, a close relative of Ptch that translocates cholesterol between intracellular membranes ([@bib6]).

Ptch1/2 mutations drive the formation of several tumors, and an important ramification of our findings is that Ptch1/2 disruption enhances not only cell autonomous Hh responses, but also Smo activation in adjacent cells with intact Ptch1/2 activity ([@bib3]). The finding that genetically normal stromal cells respond to Shh expressing tumors by infiltrating and supporting them heightens the importance of our observations because Ptch1/2 loss in the tumor may affect Shh sensitivity in supporting stromal cells non-cell autonomously ([@bib53]). Our results also predict that even in the absence of Ptch1/2, cells remain sensitive to Hh ligands signaling in nearby cells. Anticancer strategies based on ligand sequestration or inactivation therefore remain viable treatment options.

Hh signaling plays many critical roles during development as a morphogen. Responding cells interpret graded Hh ligand distributions, resulting in stereotyped patterning, and Ptch1/2 have complex roles in this process. As Hh receptors, Ptch1/2 bind extracellular Shh and initiate the response. In Drosophila, Ptch activation results in the accumulation of phosphatidylinositol 4-phosphate that in turn activates Smo via its intracellular C-terminal domain ([@bib35]; [@bib54]), a mechanism conserved in vertebrates ([@bib35]). Invariably, Hh signaling induces *Ptch1/2* expression ([@bib27]) and Ptch1/2 induction then leads to negative feedback, possibly by secreting more Smo inhibitor, increasing Shh sequestration, or both. Our finding that Ptch1/2 inhibit the Hh response non-cell autonomously, even in nEBs devoid of Shh ligand, supports the notion that the non-cell autonomous inhibition mediated by Ptch1/2 is mediated by the antiporter activity of Ptch1/2, rather than by ligand sequestration. The ability of relatively few Ptch1/2 expressing cells to inhibit the Hh response pathway further supports this idea.

Together these findings indicate that Ptch1/2 act broadly and communally inhibit Smo in tissues undergoing patterning. According to this model, local sensitivity to Shh is highly buffered and equalized between cells, aiding the formation of a smooth response gradient in the Shh morphogenetic field.

Materials and methods {#s4}
=====================

Cell lines {#s4-1}
----------

*Ptch1*^+/LacZ^ and *Ptch1*^LacZ/LacZ^ mESCs were gifts from Dr. Matthew Scott (Stanford University and HHMI). Identity of these lines was confirmed by the presence of the *LacZ* recombination in the *Ptch1* locus, the presence of 40 chromosomes per cell, and mouse-specific DNA sequences of the edited genes. *Smo*^-/-^ mESCs were a gift from Dr. Andrew McMahon (University of Southern California), and their identity was confirmed by the presence of the *ROSA26:LacZ* locus and the absence of *Smo*. HB9:GFP mESCs were a gift from Dr. Thomas Jessell (Columbia University). Their identity was confirmed by the presence of the *Hb9:gfp* transgene. *Disp1*^-/-^ mESCs and wild type (AB1) mESCs, and mESCs overexpressing Shh were previously described ([@bib19]). Identity of these lines was confirmed by the presence of 40 chromosomes per cell, and mouse-specific DNA sequences of the edited genes. mESC lines were maintained using standard conditions in dishes coated with gelatin, without feeder cells. Cells were routinely tested for Mycoplasm by Hoechst stain, and grown in the presence of tetracycline and gentamycin at regular intervals. Cultures with visible Mycoplasma infection were discarded. None of the cell lines used in this study is listed in the Database of Cross-Contaminated or Misidentified Cell Lines.

Materials {#s4-2}
---------

Cyclopamine was a gift from Dr. William Gaffield (USDA) ([@bib23]). SAG was from EMD Biochemicals (Darmstadt, Germany). Retinoic acid was from Sigma/Aldrich (St. Louis, MO).

Immunostaining {#s4-3}
--------------

Mouse anti-Pax7 (RRID:[AB_528428](https://scicrunch.org/resolver/AB_528428)), anti-Pax6 (RRID:[AB_528427](https://scicrunch.org/resolver/AB_528427)) and anti-Nkx2.2 (RRID: [AB_2314952](https://scicrunch.org/resolver/AB_2314952) [AB_531794](https://scicrunch.org/resolver/AB_531794)), were obtained from the Developmental Studies Hybridoma Bank. Goat anti-Olig2 (RRID: [AB_2157554](https://scicrunch.org/resolver/AB_2157554)) was purchased from R&D Systems (Minneapolis, MN). Guinea pig anti-Isl1/2 was a gift from Dr. Thomas Jessell (Columbia University). In all experiments, donkey and goat Alexa-488 anti-mouse, goat Alexa-568 anti-guinea pig and donkey Alexa-568 anti-goat were used as secondary antibodies. nEBs were mounted in Fluormount-G and positive nuclei were quantified. Fixation was performed for 10 min on ice using 4% paraformaldehyde in 1X PBS. Native HB9:GFP fluorescence was imaged directly, after fixation and mounting, without antibody detection.

Imaging and quantification of nuclear progenitor markers {#s4-4}
--------------------------------------------------------

Mounted nEBs were imaged with a Zeiss Observer fluorescence microscope with a 20x objective. Within each experiment, stacks were de-convolved and resulting image files were scrambled for unbiased, blind counting.

Fluorescent tracking of cells {#s4-5}
-----------------------------

Cells were singularized and washed twice with PBS. Cells were stained with 20 µM CellTracker Blue CMAC or CellTracker Green CMFDA (Thermo Fisher Scientific, Waltham MA) in DFNB for 45 min. The cells were mixed as described above, incubated at 37°C with agitation (\~0.8 Hz) for 48 hr, fixed in 4% PFA for 10 min, and mounted for microscopy. Signal was insufficient at 72 hr.

Neuralized embryoid body differentiation {#s4-6}
----------------------------------------

mESCs were differentiated into nEBs using established procedures ([@bib52]). nEBs were aggregated for 48 hr in DFNB medium in Petri dishes rotated at 0.8 Hz. 2 µM Retinoic Acid (RA) was added at 48 hr. nEBs were fixed 48 hr after the addition of RA for antibody staining of neural progenitors. nEBs were fixed 96 hr after the addition of RA for imaging and quantifying HB9:GFP fluorescence.

Reporter gene assay for Ptch1:LacZ activity {#s4-7}
-------------------------------------------

nEBs were collected, washed once in PBS and lysed in 100 mM potassium phosphate, pH 7.8, 0.2% Triton X-100. Lysates were analyzed using the Galacto-Light chemiluminescent kit (Applied Biosciences, Foster City, CA) for Ptch1:LacZ expression level. Lysates were normalized for total protein using the Bradford reagent (BioRad, Hercules, CA). At least three technical replicates are reported for each measurement.

Genome editing {#s4-8}
--------------

TALEN constructs, transfection, mESC clone selection and genotyping, and domain architectures for TALEN constructs targeting *Shh* and *Ptch2* were previously described ([@bib1]). *Ptch1* and *Smo* were targeted similarly. We repeated the protocol sequentially in mESC lines to generate complex mutant genotypes. Repeat variable domain architectures for TALEN constructs targeting *Ptch1* and *Smo* were: *Ptch1 (*5') NN NN HD HD NG HD NN NN HD NG NN NN NG NI NI and (3') HD HD HD NN HD HD NN HD HD NN NN HD HD NG NN HD HD NG NN *Smo* (5') NN HD NG NN HD NG NN NN NG NI HD NG NN HD NG and (3') HD HD HD NN HD NG HD NI NI NN NN HD HD NN HD HD HD.

sgRNAs were designed using the online CRISPR Design tool (<http://tools.genome-engineering.org>). Duplexed oligos (5') CACCGCTGTCGCTGTGATGAACACG (3'), (5') CACCGAACACGTGGCAAAAAGCAGC (3') and (5') CACCGAATGAACTACAATTCGGAAT(3'), (5') CACCGGCTCACCAGTGACCCTTATC (3') bracketing exon 1 and exon 2 of mouse *7dhcr* were cloned into pX459 ([@bib42]). *Shh*^-/-^ mESCs were transfected and transiently selected with puromycin and individual clones isolated.

Genotyping {#s4-9}
----------

PCR screening for *Ptch2* and *Shh* was previously described ([@bib1]). PCR screening was performed on cell lysates using primers flanking the *Ptch1* and *Smo* TALEN binding sites: *Ptch1*: (5') GCAAAGACCTCGGGACTCA (3') and (5') GGAGGGAGGGTTTGAATTTTT (3'). *Smo*: (5\') GCACCGGTCGCCTAAGTAGC (3\') and (5\') GCACACGTTGTAGCGCAAA (3\'). Deletions of *7dhcr* sequences were confirmed by PCR using primers (5\') AGATCCTGCACAAAGCGCAC (3\') and (5\') ACAGGCTGAGTAAGCCTTCAAGC (3\') amplifying a 300 bp fragment after the anticipated edit, and absence of a PCR product using (5\') TCAGTCTCACGCAGCAAGCAG (3\') and (5\') AGATCCTGCACAAAGCGCAC (3\'). Individual clones were confirmed by sequencing.

Mutations {#s4-10}
---------

*Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ and *Ptch1*^LacZ/LacZ^;*Shh*^-/-^ mESCs were previously described ([@bib1]). *Ptch1*^+/LacZ^;*Shh*^-/-^ were heterozygous for 1 bp and 10 bp deletions in *Shh* exon 1. *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Shh*^-/-^ mESCs were heterozygous for a 1 bp insertion and a 4 bp deletion in *Shh* exon 1. *Ptch1*^LacZ/LacZ^;*Smo*^-/-^ were heterozygous for 90 bp and 110 bp deletions in *Smo* exon 1. *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^*;Smo*^-/-^ mESCs were homozygous for an 83 bp deletion in *Smo* exon 1. *Disp1*^-/-^;*Shh*^-/-^ were heterozygous for 16 bp and 35 bp deletions in *Shh* exon 1. *Disp1*^-/-^;*Shh*^-/-^*;Ptch1*^-/-^mESCs were additionally homozygous for a 1 bp deletion in *Ptch1* exon 1. *Disp1*^-/-^;*Shh*^-/-^*;Ptch1*^-/-^;*Ptch2*^-/-^ mESCs were additionally heterozygous for 57 bp and 10 bp deletions in *Ptch2* exon 2. *Shh^-/-^* mESCs were heterozygous for 4 bp and 5 bp deletions in *Shh* exon 1. *7dhcr*^-/-^; *Shh*^-/-^ mESCs were homozygous for a 200 bp deletion encompassing exons 1 and 2 of *7dhcr*.

Statistics, replicates and confidence intervals {#s4-11}
-----------------------------------------------

In neural progenitor experiments, technical replicates were independent nEBs. At least 20 nEBs were counted. In Ptch1:LacZ and Gli:Luciferase experiments, technical replicates were independent measurements of a sample lysate. At least three measurements were performed. Outlying technical replicates were never excluded. For all experiments, biological replicates were independent differentiation experiments. Three confirmatory biological replicates were required before reporting, unless stated in figure legend. Biological replicates were disqualified rarely and only when previously characterized and published (\>10 confirmatory biological replicates) monotypic nEBs serving as controls (*Smo^-/-^, Ptch1^LacZ/LacZ^, Ptch1^LacZ/LacZ^;Ptch2^-/-^)* failed to differentiate as expected. Student's t-test was used for all experiments because data was assumed to be normally distributed. Null hypothesis values were obtained by averaging mean and standard deviations of monotypic nEBs and obtaining the inverse of the cumulative normal distribution (N = 10). Median p-values of t-tests between the counts and 10 independent sets of null hypothesis values were reported. This null hypothesis assumes equal contribution of each cell population to nEBs and exclusively cell-autonomous regulation.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for resubmitting your work entitled \"Patched1 and Patched2 inhibit Smoothened non-cell autonomously\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Janet Rossant (Senior editor), a Reviewing editor, and two reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

In this revised ms by Roberts et al., the authors test whether the Hh receptors Ptch1 and 2 act non-autonomously to repress Hh signaling in adjacent cells. The authors conclude that a Smoothened inhibitor is secreted by Ptch1/2 expressing cells that acts non-autonomously to inhibit Hh signaling. The mechanism of Ptch inhibition of Hh signaling remains poorly understood and answering this question will be of broad interest. The idea that Ptch might act non-autonomously to inhibit Shh signaling has been around for a some time in the field. Nevertheless the evidence one way or the other has been weak. The additions and alterations the authors have made to their study deal with some of the criticisms that were raised in the initial review. The authors have strengthened their argument by simplifying the flow and presentation of the data and including additional markers in their assays.

Major Comments:

1\) The role of Ptch2 in suppressing ligand independent Hh signing in the in vitro assays appears to differ from in vivo, where Ptch2 is thought to have little activity. In the Discussion the authors speculate that Ptch2 levels differ between \'ventral\' Ptch1 LacZ/LacZ; Shh-/-, and \'more dorsal\' Disp-/-, Ptch1 -/-; Shh-/-, genotypes. This could be tested by qPCR.

2\) The authors continue to rely on mixing cells of different genotypes. They provide some evidence that the initial ratios of different cell types are maintained at the later assay time points ([Figure 3K](#fig3){ref-type="fig"}). However this assay appears to show substantial segregation of some of the genotypes within an EB. Whether some of the cell lines are mixing less well than others might change the interpretation and the authors should address this.

3\) Text in the Results implies that it is ([Figure 1R](#fig1){ref-type="fig"}). This suggests that some Shh signaling is being transduced in these cells and raises questions about the whether these cells can be used to make the epistasis conclusions that the authors propose.

4\) [Figure 1U](#fig1){ref-type="fig"}. Why do Ptch1/2 null fibroblasts have \'low\' Shh pathway activity?

5\) The authors provide evidence that co-culture of Ptch1 Lacz/Lacz;Ptch2-/-;Shh-/- with Smo-/- cells significantly decreased Nkx2.2+ cells and significantly increased Olig2+ cells. This experiment reintroduces Shh expressing cells into the system (from the Smo-/- cells). This seems to be what the authors are trying to avoid in most experiments in order to simplify interpretation. Smo-/- cells have the effect of reducing Nkx2.2 in neighbouring cells, which is rationalized as being due to the presence of Ptch in these cells, however the effect is \'mild\', as Ptch activity itself is reduced by the Shh produced by the Smo-/- cells. This experiment and the convoluted interpretation seems to add little clarity, especially as the comparison is between Ptch1-/-;Ptch2-/-Smo-/- (which have no non-cell autonomous effect on Nkx2.2/Olig2), and Smo-/- (which have slightly reduced Nkx2.2 and increased Olig2).

6\) [Figure 3](#fig3){ref-type="fig"}: Why are LacZ levels as low (or lower) in Ptch1 LacZ/+ EBS (which produce Shh) as in Ptch1 LacZ/+; Shh-/-? The presence of Shh in Ptch1 LacZ/+ EBS should induce Ptch1 LacZ. Why are LacZ levels lower in Ptch1 LacZ/LacZ; Smo -/- than in Ptch1 LacZ/LacZ; Ptch2-/-; Smo -/-? Smo-/- should abolish all signaling in both cases equivalently.

7\) It is unclear how to the DHCR7 data should be interpreted. Why is there a larger inhibition of Hh signaling by 7DHC in cells cocultured with shh-/- or shh-/-;dhcr7-/- cells ([Figure 4C](#fig4){ref-type="fig"})? The authors suggest that it could be because Ptch1/2 processes 7DHC into a more potent non-autonomous inhibitor. However it is important to note that deleting DHCR7 or addition of 7DHC to cells will also have substantial feedback effects on cholesterol biosynthetic pathway that could effect multiple cellular processes, notably vesicle trafficking and/or cilia formation. The effects observed in these experiments could therefore be indirect because a change in e.g. vesicle trafficking.

8\) The authors will be aware of the recent paper from the Beachy lab- Sever et al. (PNAS) which proposes that instead of 7DHC, 7DHC processed to an oxysterol derivative are the inhibitors. This should be acknowledged

9\) [Figure 6](#fig6){ref-type="fig"}. The three part mosaics of Ptch1 LacZ/LacZ; Shh-/- or Ptch1 LacZ/LacZ; Ptch2-/-; Shh-/- cells facilitated robust Shh-mediated HB9:GFP+ expression. In contrast, negligible GFP in EBs comprised of Ptch1 LacZ/+; Shh-/- As Ptch1 LacZ/LacZ; Shh-/- cells are unable to inhibit HB9 induction by Shh producing cells this implies that Ptch2 is unable to mediate the same non-autonomous effect as Ptch1. However, this seems inconsistent with [Figure 6B,D](#fig6){ref-type="fig"} where the presence of Ptch2 is sufficient for inhibition, albeit in the absence of Disp. They make an argument about Disp preventing secretion of Ihh and Dhh, however if these ligands were relevant their activity would be evident in the control EBs lacking the 1% Shh producing cells (but still expressing Disp). [Figure 6E,F](#fig6){ref-type="fig"} a very minor fraction of PtcH^+^/LacZ appears able to inhibit HB9+- this suggests considerable range and potency of inhibitory species.

\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"Patched1 and Patched2 inhibit Smoothened non-cell autonomously\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Janet Rossant as the Senior Editor. Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work cannot be considered further for publication in *eLife*.

Although all three reviewers found the work of high quality and potentially interesting, the consensus opinion was that there was still a great deal of work required to support the conclusions of the manuscript. Given the time it would take to perform these lengthy additional experiments, we felt it would be most fair to return the paper to you. If in the future, you feel you can address these concerns, we would be open to receiving a new manuscript on the topic and would make every effort to return this to the same reviewers.

Reviewer \#1:

In this study Roberts and Roelink use the directed differentiation of wild-type and mutant mouse ES cells to provide evidence that the Hh receptors Ptch1 and 2 act non-autonomously to repress Hh signaling in adjacent cells. They propose that this is due to the secretion of a Smoothened inhibitor by Ptch1/2 expressing cells.

The mechanism of Ptch inhibition of Hh signaling is still poorly understood and the authors are tackling this important question. Although, the idea that Ptch might act non-autonomously to inhibit Shh signaling was proposed several years ago the evidence to support this has been weak and it has remained controversial. The authors\' approach to this question is novel and has the potential to provide new insight. However for this study to make a significant contribution to the field several issues need to be addressed.

The first 4 figures of this study establish the reagents the authors then use to test a non-autonomous function of Ptch1/2. While the results appear consistent with the authors\' interpretation, the experiments and interpretations need to be strengthened:

The authors rely on mixing cells of different genotypes and assume that the initial ratios of different cell types are maintained at the assay time points. Independent markers (e.g. ubiquitously expressed fluorescent markers) for each of the cell types could be used to demonstrate that the ratios are maintained. This is important because differences in initial set up, growth rates, cell competition or adhesion could be involved. This would change the interpretation of the data.

For example in Figure 7 the authors indicate that they used 1% of cells of a particular genotype. In an EB with c.1000 cells this makes 10 cells with probably considerable variation.

The assays relay either on population, LacZ levels, or the MN marker HB9. LacZ lacks the single cell resolution one would like to see in these assays. HB9 induction is not a direct target of Shh signaling (it is induced in motor neurons that as they differentiate and become post mitotic) and is only expressed in one dorsal-ventral region of the spinal cord. A reduction in HB9 expression could result from either decreased Shh signaling (as the authors conclude) or from increased Shh signaling (if Nkx2.2 expressing progenitors are induced) or from decreased neuronal differentiation (if e.g. pro neural genes are inhibited). Use of a greater range of markers and single cell resolution would greatly strengthen the argument.

The authors argue from the mosaic experiments in Figure 7C,D that the inhibitory activity of Ptch1/2 on adjacent cells is not due to an unknown downstream factor produced by these cells. For this argument they rely on Ptch1-/-;Ptch2-/-;Smo-/- mESCs. However these cells might not be completely inert. The authors state that Ptch1LacZ/LacZ;Ptch2-/-;Smo-/- NEBs expressed Pax7 (p7). However the data in [Figure 1R](#fig1){ref-type="fig"} seems to indicate that the amount of Pax7 expression is substantially reduced compared to the other genotypes. This suggests that some Shh signaling is being transduced in these cells and raises questions about the strict epistasis the authors refer to. It also weakens the case for ruling out an unknown factor.

More generally, a limitation of the study is the use of a single experimental design strategy -- uncontrolled aggregation of unmarked ESCs of different genotypes. Use of alternative approaches or refining this assay approach is probably required to rigorously test the authors\' model. For example:

Marking cells of different genotypes and assembling aggregates with controlled arrangements of different genotypes would remove much of the ambiguity from the data.

Clarifying if the secretion of the inhibitory molecule is the only function of Ptch or if cell-autonomous repression of the Hh pathway involves an independent action of Ptch would be an important insight.

Addressing whether the non-autonomous inhibitory activity is secreted or whether cell contact is necessary would also be an important piece of information. For this type of experiment, the use of transwell assays, or similar, could be used.

Since Ptch molecules have been shown to restrict the spread of Hh ligands in some tissues, the increased Hh response in Ptch double mutant cells could reflect a better spread of Hh ligands through an EB. The authors need to more clearly rule this out.

Reviewer \#2:

In the manuscript by Roberts and Roelink, the authors address one of the enduring mysteries of Hh signal transduction, how does Ptch regulate Smo? The authors make two observations. First, through a complex series of experiments using numerous embryonic stem cells lines that lack key components of the Hh pathway, the authors demonstrate that Ptch2 (in the absence of Ptch1) is capable of inhibiting Smo. In a second series of experiments, through co-culture methods, the authors show that the Ptch1 and Ptch2 are capable of inhibiting Smo via non-cell autonomous interactions. From these studies, the authors conclude that Ptch1 and Ptch2 mediate the secretion of a factor that inhibits Smo activation in nearby cells.

Many of the initial experiments support an earlier paper published by the lab (Alfaro et al., 2014). While the experiments presented in this paper were more extensive and genetically clean than those published earlier, the results closely echo conclusions made in the earlier study. The results from the co-culture experiments are novel, interesting, and have important implications for understanding Ptch1-Smo regulation and Hh signaling in tissues. Through multiple experiments, the authors make a case for the existence of a secreted factor mediated by Ptch1/2 that is capable of inhibiting Smo activity. While no factor is directly identified, its existence is intriguing and would be a significant contribution to the large body of work that has been dedicated towards understanding the interaction between Ptch and Smo. While I have some concerns regarding experimental controls (please refer to the Major Issues below), if these can be addressed then I would recommend this manuscript for publication.

Major Issues:

1\) In multiple tissue types, Hh signaling has been shown to play a critical role in progenitor cell maintenance. Thus, one could argue that the shifts observed in [Figure 1](#fig1){ref-type="fig"} could be due to changes in progenitor abundance and not due to changes in progenitor identity. While it may be anecdotal, this is actually supported by [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, in which the control NEB is by far the largest and is made up of more ventral progenitors than the PtchLacZ/LacZ; Ptch2-/-, Smo-/- NEB. For this reason, I would encourage that a few control experiments be done to determine if there are any differences in (i) progenitor abundance, (ii) neuronal abundance, and (iii) cell death across the various mESC cell lines. If NEB tissue still exists, this should be fairly easy to accomplish. One could use markers such as Caspase3 to assess for cell death, *Sox2* (or any broadly expressed progenitor marker) to assess for progenitor abundance, and Tuj1 or Neun (or any broadly expressed neuronal markers) to assess for neuronal abundance. If there is variability in any of these three factors, the data needs to be normalized to account for these differences.

2\) In many of the LacZ measurements, there is no normalization for total viable cell number from which the measurement is being done. In its absence one cannot determine whether a change in LacZ activity is due to changes in cell number or changes in the activity of the reporter. This issue is especially important for [Figure 5](#fig5){ref-type="fig"}-how do we know that the effects are not caused by decreases in reporter cell number. Part of the problem is that LacZ is being used as a bulk reporter, rather than a single cell reporter. It would be optimal if the authors could use LacZ measurements in single cells (e.g. by immunostaining in sectioned, chimeric NEBs or FACS) to show non-cell autonomous effects.

3\) Given the variability of the NEB size, I would recommend the authors represent the counts in [Figures 1](#fig1){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and 7 not as a number of cells per NEB, but rather as a% of cells within the NEB.

4\) In the triple chimera experiment shown in Figure 7, it seems to me that an equally likely explanation for the authors\' result is that Ptch expressing cells sequester the Shh ligand being secreted by the cells that are producing Shh→ thus leading to reduced HB9-GFP expression in the reporter cells. There is no need to invoke a cell non-autonomous ligand. The authors\' should clarify the discussion here and explain more clearly why they do not favor the sequestration model.

Reviewer \#3:

This work involves a heroic effort that produced and analyzed an impressive set of mutant mouse ESCs that inactivate components of Shh signal transduction in various combinations. The principal finding -- that cells that transduce the Shh signal also down-regulate the Shh response of nearby cells -- is supported by the presented evidence, and may represent a new feature that sculpts the landscape of responses signaling proteins. It has important general implications. I recommend publication but strongly recommend a major re-write. The text suffers throughout, and especially in the Discussion, from the trap of second order speculation (speculating on the speculations), and from descriptions and figures that are difficult to follow. Although the imaginative scope is laudable, the extent to which the authors build a hypothetical construct is not.

Samples to illustrate:

Abstract sentence \#2: \"Patched is a putative proton-driven antiporter, and this antiporter activity is required for Smoothened inhibition.\" \[Patched may well have antiporter activity, but such an activity has never been measured and it is not known if this putative activity is related to inhibition of Smoothened.\]

\"We found that the Hh response was invariably repressed by the presence of Ptch1/2 in nearby cells. \[Was it repressed or not? What does \"invariably\" add or mean in this context.\] We attribute these findings to Ptch1/2-mediated secretion of a Smo inhibitor that affects Smo activity in nearby cells.\" \[There is evidence for inhibition but no evidence for a molecular inhibitor or for secretion. Best not to use genetics to do biochemistry. If the authors want to speculate, it is important that they propose alternative possibilities and indicate which one(s) they favor. As present, the authors build an elaborate scheme by combining assumptions about how Patched works and about a hypothetical inhibitor; they would be better served by emphasizing what their experiments establish without fantasizing molecular models.

10.7554/eLife.17634.013

Author response

*Major Comments:*

*1) The role of Ptch2 in suppressing ligand independent Hh signing in the* in vitro *assays appears to differ from* in vivo*, where Ptch2 is thought to have little activity. In the Discussion the authors speculate that Ptch2 levels differ between \'ventral\' Ptch1 LacZ/LacZ; Shh-/-, and \'more dorsal\' Disp-/-, Ptch1 -/-; Shh-/-, genotypes. This could be tested by qPCR.*

This is a valid point that we have discussed in the lab a lot. Before addressing the role of Ptch2, I would like to emphasize that the central conclusion of this paper is based on the *Ptch1*^-/-^;*Ptch2*^-/-^ phenotype, and that this is conserved between the various "families" of cell lines that we have derived. We acknowledge the reality that Ptch1 and Ptch2 activity level are likely subject to selection if either paralog is lost. Our solution to this likelihood has been to generate cell lines genetically null for both paralogs. We followed the reviewers' suggestion and performed qPCR for *Ptch2* in *Ptch1*^-/-^;*Shh*^-/-^ and *Disp1*^-/-^;*Ptch1*^-/-^;*Shh*^-/-^mESC lines, whose nEBs have differing degrees of ventral identity. *Ptch2* levels are elevated in both lines, relative to wild type cells, and this is specific to differentiating cells, as no differences were detected between cell lines grown in pluripotent culture. *Ptch2* was decreased in *Ptch1*^-/-^;*Shh*^-/-^ nEBs, relative to *Disp1*^-/-^;*Ptch1*^-/-^;*Shh*^-/-^ nEBs, in agreement with our model of Ptch2 as a cell non-autonomous negative regulator of the Shh pathway. This effect was not quite statistically significant (*t-test,* n=3) but trended toward support for our model. We note with interest the relatively large effect that small differences in *Ptch2* expression may have on nEB identity in the absence of Ptch1 (see also comment 9). Nevertheless, we would like to stress the importance of experiments in which cells are genetically null for [both]{.ul} *Ptch1* and *Ptch2,* and thus not subject to variation in *Ptch2* levels.10.7554/eLife.17634.011Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.17634.011](10.7554/eLife.17634.011)

*2) The authors continue to rely on mixing cells of different genotypes. They provide some evidence that the initial ratios of different cell types are maintained at the later assay time points ([Figure 3K](#fig3){ref-type="fig"}). However this assay appears to show substantial segregation of some of the genotypes within an EB. Whether some of the cell lines are mixing less well than others might change the interpretation and the authors should address this.*

Using the cell tracker dyes, we always find that the initial mixing of mESC cells with distinct genotypes is "pepper and salt". On occasion, and observed more frequently when the constituent cells acquire different identities, we find that the cell sort in with "like" neighbors. There are two important considerations. 1) Given that we find non cell autonomous effects even in our LacZ assays at early time points, at least some of the critical interactions must take place soon after the nEBs have formed, and are still random in regard to their mosaic distribution. 2) The observed "sorting" of the cells would decrease the number of contacts, and decrease the proximity, between cells with different genotypes and, therefore, suppress the non-autonomous effects we observe in the mosaic nEBs. Sorting alone cannot explain the non-cell autonomous effects we observe, and thus does not affect our conclusions. If anything, the sorting will mask the full extent of the non-autonomous interactions between cell with distinct genotypes.

*3) Text in the Results implies that it is ([Figure 1R](#fig1){ref-type="fig"}). This suggests that some Shh signaling is being transduced in these cells and raises questions about the whether these cells can be used to make the epistasis conclusions that the authors propose.*

It would seem like that part of this comment was lost, but we assume that this comment is about some level of Hh pathway activation in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^;*Smo*^-/-^ cells. This could be concluded from the fewer Pax7 cells seen after differentiation, but perhaps even more so from the higher level of Ptch1:LacZ as shown in [Figure 3A](#fig3){ref-type="fig"}. These cells have been derived from Matthew Scott's Ptch1^LacZ/LacZ^mESCs and have undergone some evolution in vitro, reflected in a somewhat less dorsal identity after *Smo* removal. Importantly, under all conditions where we accept/reject the null hypothesis (cells within a mosaic do not affect each other) we take into account levels of LacZ or ventral cells present in the non-mosaic conditions

*4) [Figure 1U](#fig1){ref-type="fig"}. Why do Ptch1/2 null fibroblasts have \'low\' Shh pathway activity?*

We were struck by this observation as well, and we have submitted a paper that studies the Hh response in these cells in depth (Casillas et al., Science Signaling, under review). Importantly, we demonstrate that in *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ ES cells the Hh response is not upregulated under normal culture conditions, but only becomes active a few days after serum withdrawal ([Figure 3C](#fig3){ref-type="fig"}). We hypothesize that the *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ fibroblasts have inherited this low level of pathway activation we observe in cultured ES cells lacking *Ptch1* and *Ptch2*. This observation demonstrates that, even in the absence of all Ptch1/2 activity, Smo is not necessarily active. In the submitted paper (Casillas et al.) we show that the *Ptch1*^LacZ/LacZ^;*Ptch2*^-/-^ fibroblasts are insensitive to the Smo inhibitor vismodegib, but that the Hh response can be activated after *Shh* transfection into these cells requiring the N-terminal Cysteine-rich domain (CRD), providing a mechanism of Smo activation distinct from the loss of Ptch1/2 inhibition. We feel these studies illustrate that mechanistic insights remain to be discovered even though at first glance they seem to be at odds with canonical models for Hh signaling. Of note is a recent Nature paper (Byrne et al., July 26 2016) that demonstrates a cholesterol binding pocket in the N-terminal extracellular Cysteine-rich domain (CRD), that is required for Hh signal transduction, further suggesting orthosteric regulation of Smo activity via the CRD.

*5) The authors provide evidence that co-culture of Ptch1 Lacz/Lacz;Ptch2-/-;Shh-/- with Smo-/- cells significantly decreased Nkx2.2+ cells and significantly increased Olig2+ cells. This experiment reintroduces Shh expressing cells into the system (from the Smo-/- cells). This seems to be what the authors are trying to avoid in most experiments in order to simplify interpretation. Smo-/- cells have the effect of reducing Nkx2.2 in neighbouring cells, which is rationalized as being due to the presence of Ptch in these cells, however the effect is \'mild\', as Ptch activity itself is reduced by the Shh produced by the Smo-/- cells. This experiment and the convoluted interpretation seems to add little clarity, especially as the comparison is between Ptch1-/-;Ptch2-/-Smo-/- (which have no non-cell autonomous effect on Nkx2.2/Olig2), and Smo-/- (which have slightly reduced Nkx2.2 and increased Olig2).*

We agree that the removal of *Smo* from the "driver cells" does not add new insights into the non-autonomous inhibition. We do think that this experiment has significant confirmatory value in that it lends support for its accompanying mosaic experiment using different cell lines, making it an independent test of our hypothesis. Because the cells are null for *Smo*, we interpret ventrally fated cells in the mosaic nEBs to be lineage restricted to the "readout" cells. We agree that in most experiments, absence of Shh from the system is a major advantage. In this case we reason that because *Ptch1*^-/-^;*Ptch2*^-/-^ "readout" cells cannot respond to ShhN ([Figure 1T](#fig1){ref-type="fig"}), the experiment has utility. We also reason that Shh in the mosaic nEB should have no effect on *Smo*^-/-^ cells due to the Hh pathway's quiescence. We have assembled a new supplemental Figure ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) that shows a diagram explaining that the loss of Nkx2.2 in conjunction with a gain of Olig2 is indicative of the acquisition of a more dorsal fate, albeit in subtle fashion.

*6) [Figure 3](#fig3){ref-type="fig"}: Why are LacZ levels as low (or lower) in Ptch1 LacZ/+ EBS (which produce Shh) as in Ptch1 LacZ/+; Shh-/-? The presence of Shh in Ptch1 LacZ/+ EBS should induce Ptch1 LacZ. Why are LacZ levels lower in Ptch1 LacZ/LacZ; Smo -/- than in Ptch1 LacZ/LacZ; Ptch2-/-; Smo -/-? Smo-/- should abolish all signaling in both cases equivalently.*

We have no good explanation why under those conditions where we do not detect a measurable Hh response after differentiation ([Figure 1A](#fig1){ref-type="fig"}) we do get variable levels of LacZ. Importantly, *Ptch1* promotor activity (which is measured with the LacZ) is not exclusively on the control of Smo activity, and low levels might vary due to reasons unknown to us. The contribution of the *Shh* locus remains minimal. The loss of Shh causes a slight increase in the number of Pax7 positive cells as compared to the equivalent cell line with the Shh locus intact (Figure 1AC), while the loss of Shh causes a small increase in Ptch1 promotor activity ([Figure 3A](#fig3){ref-type="fig"}). In both cases we consider the Hh response to be effectively off, despite the variable low levels of LacZ.

*7) It is unclear how to the DHCR7 data should be interpreted. Why is there a larger inhibition of Hh signaling by 7DHC in cells cocultured with shh-/- or shh-/-;dhcr7-/- cells ([Figure 4C](#fig4){ref-type="fig"})? The authors suggest that it could be because Ptch1/2 processes 7DHC into a more potent non-autonomous inhibitor. However it is important to note that deleting DHCR7 or addition of 7DHC to cells will also have substantial feedback effects on cholesterol biosynthetic pathway that could effect multiple cellular processes, notably vesicle trafficking and/or cilia formation. The effects observed in these experiments could therefore be indirect because a change in e.g. vesicle trafficking.*

It is important to note that we measure the Hh response only in cells that are genetically intact for DHCR7, and are thus "normal" in their cholesterol synthesis pathway. We agree that the loss of *dhcr7* can result in significant changes in a cell, but it is reasonable to assume that effects on vesicle trafficking and/or cilia formation are cell autonomous, and thus restricted to a mosaic compartment in which we do not measure the Hh response. It is indeed remarkable that altered cholesterol biosynthesis, can affect the Hh response in cells with a normal cholesterol biosynthesis, but lacking *Ptch1/2*.

The addition of 7DHC is indeed more complex, since both compartments in the mosaic are equally exposed. It is true that 7DHC inhibits the Hh response in cells lacking *Ptch1/2*, but our mosaic experiments demonstrate that the inclusion of *Ptch1/2* containing cells exacerbates the inhibitory effect of 7DHC on cells that lack *Ptch1/2*. We hypothesize that this non autonomous effect is mediated by Ptch1/2 activity. We have added additional clarifying interpretive language to the text.

*8) The authors will be aware of the recent paper from the Beachy lab- Sever et al. (PNAS) which proposes that instead of 7DHC, 7DHC processed to an oxysterol derivative are the inhibitors. This should be acknowledged*

This paper came out the same day we submitted, and we have added references to this relevant paper in the revised manuscript.

*9) [Figure 6](#fig6){ref-type="fig"}. The three part mosaics of Ptch1 LacZ/LacZ; Shh-/- or Ptch1 LacZ/LacZ; Ptch2-/-; Shh-/- cells facilitated robust Shh-mediated HB9:GFP+ expression. In contrast, negligible GFP in EBs comprised of Ptch1 LacZ/+; Shh-/- As Ptch1 LacZ/LacZ; Shh-/- cells are unable to inhibit HB9 induction by Shh producing cells this implies that Ptch2 is unable to mediate the same non-autonomous effect as Ptch1. However, this seems inconsistent with [Figure 6B,D](#fig6){ref-type="fig"} where the presence of Ptch2 is sufficient for inhibition, albeit in the absence of Disp. They make an argument about Disp preventing secretion of Ihh and Dhh, however if these ligands were relevant their activity would be evident in the control EBs lacking the 1% Shh producing cells (but still expressing Disp). [Figure 6E,F](#fig6){ref-type="fig"} a very minor fraction of PtcH^+^/LacZ appears able to inhibit HB9+- this suggests considerable range and potency of inhibitory species.*

We reached similar conclusions and agree with these comments. We suspected that differences in GFP induction in these two families of mESC lines might stem from differences in Ptch2 expression. Our qPCR data submitted with this revision supports this view (see comment 1). We agree that the range and potency of the inhibitory species has great relevance to elucidating the Hh signaling mechanism. We agree that contributions from Ihh and Dhh are unlikely, but it is still formally possible that control nEBs lacking Shh expressing cells are marginally activated by Dhh/Ihh at low levels insufficient to activate HB9:GFP. The use of *Disp^1^*^-/-^mESCs serves as an additional safeguard against this possibility, as well as an independent hypothesis test.

\[Editors' note: the author responses to the first round of peer review follow.\]

*Reviewer \#1:*

*The authors rely on mixing cells of different genotypes and assume that the initial ratios of different cell types are maintained at the assay time points. Independent markers (e.g. ubiquitously expressed fluorescent markers) for each of the cell types could be used to demonstrate that the ratios are maintained. This is important because differences in initial set up, growth rates, cell competition or adhesion could be involved. This would change the interpretation of the data.*

We used vital cell markers (Cell Tracker dyes) to determine that cells contributed to mosaic nEBs in the predicted ratios and demonstrate this data for the most quantitative assays used.

The mosaic contribution in nEBs did not differ from predicted. Dye signal persisted reliably for 60h in mosaic nEBs, and we limited their use to the shorter (LacZ) experiments. We were unable to generate a truly ubiquitously expressed fluorescent marker as mESCs silenced at some rate all constructs using a ubiquitous promoter, and thus we could only rely on the vital dyes.

*For example in Figure 7 the authors indicate that they used 1% of cells of a particular genotype. In an EB with c.1000 cells this makes 10 cells with probably considerable variation.*

*The assays relay either on population, LacZ levels, or the MN marker HB9. LacZ lacks the single cell resolution one would like to see in these assays. HB9 induction is not a direct target of Shh signaling (it is induced in motor neurons that as they differentiate and become post mitotic) and is only expressed in one dorsal-ventral region of the spinal cord. A reduction in HB9 expression could result from either decreased Shh signaling (as the authors conclude) or from increased Shh signaling (if Nkx2.2 expressing progenitors are induced) or from decreased neuronal differentiation (if e.g. pro neural genes are inhibited). Use of a greater range of markers and single cell resolution would greatly strengthen the argument.*

We maintained use of Ptch1:LacZ because we can very accurately measure it in aggregate, which we argue is more crucial than single cell resolution. We found Ptch1:LacZ staining to be unreliable and ambiguous due to the need to integrate the frequency of positive cells and staining intensity.

We do not detect variation in our nEBs with regard to their acquisition of Pax6+ neural progenitor fate, or Tuj1+ neural fate. Use of a Sim1 reporter line to mark the most ventral neural domain was unsuccessful due to the paucity of these cells, perhaps due to their need for high signaling.

We demonstrate that HB9:GFP+ cells colabel with Isl1/2 staining, which we have found to correlate positively with Smo activation in nEBs. We also demonstrate that HB9:GFP has a positive relationship with Smo activity, as demonstrated by a range of SAG doses. Furthermore, the quantification is routinely base on the analysis of \>20 nEBs, making random variation much less of a concern.

*The authors argue from the mosaic experiments in Figure 7C,D that the inhibitory activity of Ptch1/2 on adjacent cells is not due to an unknown downstream factor produced by these cells. For this argument they rely on Ptch1-/-;Ptch2-/-;Smo-/- mESCs. However these cells might not be completely inert. The authors state that Ptch1LacZ/LacZ;Ptch2-/-;Smo-/- NEBs expressed Pax7 (p7). However the data in [Figure 1R](#fig1){ref-type="fig"} seems to indicate that the amount of Pax7 expression is substantially reduced compared to the other genotypes. This suggests that some Shh signaling is being transduced in these cells and raises questions about the strict epistasis the authors refer to. It also weakens the case for ruling out an unknown factor.*

We regret the confusion caused by our original figure and have amended it. Ptch1LacZ/LacZ;Ptch2- /-;Smo-/- mESCs reliable give rise Pax7+ cells in nEBs. Pax7+ cells arrange in distinct domains in nEBs and are rarely distributed throughout the tissue. Ptch1LacZ/LacZ;Ptch2-/-;Smo-/- cells generate smaller nEBs when cultured monotypically and it is somewhat more common to obtain nEBs devoid of Pax7+ cells in a given culture, but many nEBs are Pax7+. We demonstrate box and whisker plots for transparency with regard to this reality.

*More generally, a limitation of the study is the use of a single experimental design strategy -- uncontrolled aggregation of unmarked ESCs of different genotypes. Use of alternative approaches or refining this assay approach is probably required to rigorously test the authors\' model. For example:*

*Marking cells of different genotypes and assembling aggregates with controlled arrangements of different genotypes would remove much of the ambiguity from the data.*

We use Cell Tracker markers to address this criticism and we also employ our panel of cell lines in various combinations in order to offset these limitations and test the robustness of our assay.

*Clarifying if the secretion of the inhibitory molecule is the only function of Ptch or if cell-autonomous repression of the Hh pathway involves an independent action of Ptch would be an important insight.*

We agree with this but have elected to focus our experiments on establishing the veracity of these effects in this system, with an ultimate ambition to more mechanistically interrogate it with more extensive gene editing. We view these planned experiments as beyond the scope of this study. Current approaches restrict us to expressing Ptch1/2 variants in Ptch1/2 null cells to test these mechanistic subtleties. We elect to limit our conclusions at this time to Ptch1/2 effects when expressed endogenously. We will use gene editing to generate mutations in cell lines in the future.

*Addressing whether the non-autonomous inhibitory activity is secreted or whether cell contact is necessary would also be an important piece of information. For this type of experiment, the use of transwell assays, or similar, could be used.*

We agree with this notion. However, we elect to use the privileged environment within the nEB because of its heightened physiological relevance. We are dubious as to whether Ptch1/2 expressed at levels meaningful for a realistic induction response can condition medium as has been reported in fibroblasts, for example. Nor do we value that observation highly given the reality of signaling in the embryo, where cells are in close contact. Our experiments to date using medium conditioned by mESCs with or without Ptch1/2 failed to show Smo modulating activity.

*Since Ptch molecules have been shown to restrict the spread of Hh ligands in some tissues, the increased Hh response in Ptch double mutant cells could reflect a better spread of Hh ligands through an EB. The authors need to more clearly rule this out.*

We demonstrate using live staining with 5E1 anti-Shh that Shh distribution within cell lines in our panel does not meaningfully differ.

Reviewer \#2:

*Major Issues:*

*1) In multiple tissue types, Hh signaling has been shown to play a critical role in progenitor cell maintenance. Thus, one could argue that the shifts observed in [Figure 1](#fig1){ref-type="fig"} could be due to changes in progenitor abundance and not due to changes in progenitor identity. While it may be anecdotal, this is actually supported by [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, in which the control NEB is by far the largest and is made up of more ventral progenitors than the PtchLacZ/LacZ; Ptch2-/-, Smo-/- NEB. For this reason, I would encourage that a few control experiments be done to determine if there are any differences in (i) progenitor abundance, (ii) neuronal abundance, and (iii) cell death across the various mESC cell lines. If NEB tissue still exists, this should be fairly easy to accomplish. One could use markers such as Caspase3 to assess for cell death, Sox2 (or any broadly expressed progenitor marker) to assess for progenitor abundance, and Tuj1 or Neun (or any broadly expressed neuronal markers) to assess for neuronal abundance. If there is variability in any of these three factors, the data needs to be normalized to account for these differences.*

We find that Pax6+ cells and Tuj+ cells exist in roughly equal frequencies in nEBs derived exclusively from each cell line and we demonstrate this now. *Sox2* expression also does not meaningfully differ although we do not show this data.

*2) In many of the LacZ measurements, there is no normalization for total viable cell number from which the measurement is being done. In its absence one cannot determine whether a change in LacZ activity is due to changes in cell number or changes in the activity of the reporter. This issue is especially important for [Figure 5](#fig5){ref-type="fig"}-how do we know that the effects are not caused by decreases in reporter cell number. Part of the problem is that LacZ is being used as a bulk reporter, rather than a single cell reporter. It would be optimal if the authors could use LacZ measurements in single cells (e.g. by immunostaining in sectioned, chimeric NEBs or FACS) to show non-cell autonomous effects.*

We address this concern by tracking contributions from cell lines in mosaic nEBs with vital dye markers, and confirm that they are as expected, and we demonstrate this data.

*3) Given the variability of the NEB size, I would recommend the authors represent the counts in [Figures 1](#fig1){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and 7 not as a number of cells per NEB, but rather as a% of cells within the NEB.*

We have performed a similar analysis where nEBs are normalized for their size and have found that it does not alter our conclusions but that the effects we report are actually more pronounced. Because we did not feel comfortable with the assumption that cell fate would be independent of nEB size, we chose to report the most conservative conclusion.

*4) In the triple chimera experiment shown in Figure 7, it seems to me that an equally likely explanation for the authors\' result is that Ptch expressing cells sequester the Shh ligand being secreted by the cells that are producing Shh→ thus leading to reduced HB9-GFP expression in the reporter cells. There is no need to invoke a cell non-autonomous ligand. The authors\' should clarify the Discussion here and explain more clearly why they do not favor the sequestration model.*

We address this concern with Shh staining, which we demonstrate is equivalent in mosaic nEBs comprised of each cell line in our panel. We have modified the Discussion making our argument that Shh sequestration (or the lack thereof) is not the main reason for the effects observed.

In short: 1) All relevant lines are Shh-/-, and thus not subject to sequestration, 2) Enhancing the SAG effects argues that the Ptch1/2 cargo is acting on Smo, and 3) no alteration of extracellular Shh distribution as a function of Ptch1/2 in the surrounding cells is observed.

*Reviewer \#3:*

*This work involves a heroic effort that produced and analyzed an impressive set of mutant mouse ESCs that inactivate components of Shh signal transduction in various combinations. The principal finding -- that cells that transduce the Shh signal also down-regulate the Shh response of nearby cells -- is supported by the presented evidence, and may represent a new feature that sculpts the landscape of responses signaling proteins. It has important general implications. I recommend publication but strongly recommend a major re-write. The text suffers throughout, and especially in the Discussion, from the trap of second order speculation (speculating on the speculations), and from descriptions and figures that are difficult to follow. Although the imaginative scope is laudable, the extent to which the authors build a hypothetical construct is not.*

We regret the confusion our original manuscript caused and have taken extensive efforts to rewrite it with greater clarity.

*Samples to illustrate:*

*Abstract sentence \#2: \"Patched is a putative proton-driven antiporter, and this antiporter activity is required for Smoothened inhibition.\" \[Patched may well have antiporter activity, but such an activity has never been measured and it is not known if this putative activity is related to inhibition of Smoothened.\]*

*\"We found that the Hh response was invariably repressed by the presence of Ptch1/2 in nearby cells. \[Was it repressed or not? What does \"invariably\" add or mean in this context.\] We attribute these findings to Ptch1/2-mediated secretion of a Smo inhibitor that affects Smo activity in nearby cells.\" \[There is evidence for inhibition but no evidence for a molecular inhibitor or for secretion. Best not to use genetics to do biochemistry. If the authors want to speculate, it is important that they propose alternative possibilities and indicate which one(s) they favor. As present, the authors build an elaborate scheme by combining assumptions about how Patched works and about a hypothetical inhibitor; they would be better served by emphasizing what their experiments establish without fantasizing molecular models.*

We have greatly revised the degree to which we draw conclusions based on our experiments and have confined our speculations.
